Alzheimer's disease and its family history reduce the risk of non‐Hodgkin's lymphoma: A Mendelian randomization study

孟德尔随机化 家族史 疾病 霍奇金淋巴瘤 医学 淋巴瘤 随机化 孟德尔遗传 肿瘤科 儿科 内科学 临床试验 遗传学 生物 基因型 基因 遗传变异
作者
Zilong Wang,Binyang Song,Jinhua Wang,Xiaobo Wang,Bo Tang
出处
期刊:Alzheimers & Dementia [Wiley]
标识
DOI:10.1002/alz.14205
摘要

We recently read Association between Alzheimer's disease and risk of cancer: A retrospective cohort study in Shanghai, China, and the results suggested that Alzheimer's disease (AD) significantly increases the risk of lymphoma.1 However, several previous studies have consistently shown an inverse correlation between AD and cancer.2-4 Currently, the association between AD and hematological diseases is predominantly studied through cohort investigations, with limited attention given to lymphoma specifically.4, 5 Hence, due to less research and conflicting results from these cohort studies, we opted for Mendelian randomization (MR), a method that offers a higher level of evidence, to explore the causal relationship between AD and lymphoma.6 We were surprised to discover that AD significantly decreased the risk of non-Hodgkin's lymphoma (NHL; about 90% of all lymphomas), but not Hodgkin's lymphoma (HL; about 10% of all lymphomas; see Table S1 and S2, detailed analyses of HL are shown in Table S3 and Figures S1–S3 in supporting information).7 We used genome-wide association studies (GWAS) data from two major publicly available databases, namely, IEU Open GWAS (https://gwas.mrcieu.ac.uk) and FinnGen (R10, https://www.finngen.fi/fi), to assemble multiple cohorts of relevant GWAS data pertaining to AD, family history of AD, NHL and HL (Table S4 and Figure S4 in supporting information). The analysis process involves five methods named MR-Egger, weighted median, inverse variance weighted (IVW), simple mode, and weighted mode, and we selected the IVW method as the primary reference index. Analysis of three cohorts of AD revealed a significant reduction in the risk of developing NHL (I: ORIVW = 0.823, PIVW = 0.046; II: ORIVW = 1.45E-15, PIVW = 0.023; III: ORIVW = 0.905, and PIVW = 0.016), indicating that AD served as a protective factor (Figure 1, Figure S5 in supporting information, and Table S1). Additionally, we examined the effects of a family history of AD and it also significantly decreased the risk of developing NHL (ORIVW = 0.777, PIVW = 0.004). In addition to the IVW method, we also observed varying degrees of statistical significance with the other four methods (Figure 1). Meanwhile, we conducted heterogeneity, pleiotropy, and sensitivity analyses of the aforementioned results using MR-Egger, MR-PRESSO (pleiotropy residual sum and outlier), and "leave-one-out" methods. The findings demonstrated the robustness and reliability of our conclusions (Table S5, Figure S6 and S7 in supporting information). Detailed methods of analysis and instrumental variable (single nucleotide polymorphisms) information used are available in the supplementary materials (Supplementary Methods and Table S6 in supporting information). In fact, we are not the first to elucidate the relationship between AD and NHL. Previous cohort studies, systematic reviews, and meta-analyses on AD and NHL have indicated that AD may serve as a protective factor, reducing the incidence of NHL.3, 4, 8 Only one MR study investigated AD in relation to follicular lymphoma (FL), a subtype of NHL, but the IVW method did not reveal a significant difference.2 It is noteworthy that FL represents only 20% to 25% of new NHL cases and cannot fully represent all NHL subtypes.9 In our study, we utilized three different cohorts to investigate the effect of AD on NHL, all of which consistently showed AD as a protective factor. Nevertheless, it is important to acknowledge that we utilized GWAS studies from European populations, whereas Ren et al. utilized data from Chinese populations. Moreover, NHL does not represent the entirety of lymphoma. The above two points may be important reasons for the difference between our results. Furthermore, we are the first to report that a family history of AD reduces the risk of developing NHL. Considering the significant role of genetic factors in AD pathogenesis, this finding extends the study's scope to a broader population and a longer timeline for understanding the relationship between the two. For instance, Valentine et al., utilizing the Utah Population Database (UPDB), identified individuals with a family history of AD as high-risk groups for AD to investigate various common diseases and cancers.10 Surprisingly, their findings indicated that high-risk groups for AD significantly elevated the risk of NHL, contradicting the conclusions drawn from other studies.10 Certainly, there is a broad spectrum of opinions regarding the mechanisms underlying the interactions between AD and NHL. While researchers have proposed a range of related mechanisms such as inflammation, immune response, infectious agents, and oxidative stress, these can only partially account for this inverse correlation.8 Clarifying the relationship between the two and identifying common pathophysiological pathways will aid clinics in developing new, optimal programs for the prevention and treatment of both AD and NHL. In conclusion, from the perspective of evidence-based medicine, the MR methodology used in our study can offer a higher level of evidence regarding the relationship between the two. This can further stimulate research on their association, aiming to elucidate the intricate mechanisms underlying the interactions between AD and NHL. All GWAS data used in our study came from the IEU OpenGWAS project and FinnGen study, and we thank both databases and all participants and investigators who participated in relevant GWAS studies. There are no relevant conflicts of interest for this publication. Author disclosures are available in the supporting information. This research was supported by the Undergraduate Teaching Reform Fund of Dalian Medical University (112007010205), the College Students' Innovation Project of Dalian Medical University (S202310161043), and the National Natural Science Foundation of China (81800203). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
安然发布了新的文献求助10
2秒前
lxgz发布了新的文献求助10
2秒前
3秒前
6秒前
超级月饼发布了新的文献求助10
8秒前
Rondab应助白日焰火采纳,获得10
9秒前
xue完成签到,获得积分10
9秒前
猪猪hero发布了新的文献求助10
10秒前
Michaelfall完成签到,获得积分10
10秒前
慕青应助DS采纳,获得10
13秒前
13秒前
干净映天完成签到 ,获得积分10
15秒前
IvyLee完成签到,获得积分10
17秒前
莫x莫完成签到 ,获得积分10
18秒前
积极冰淇淋完成签到,获得积分10
18秒前
zzm发布了新的文献求助10
18秒前
Yolo关注了科研通微信公众号
21秒前
hrrypeet完成签到,获得积分10
21秒前
TTTHANKS完成签到 ,获得积分10
22秒前
量子星尘发布了新的文献求助30
24秒前
great7701完成签到,获得积分10
24秒前
英姑应助赟糖采纳,获得10
24秒前
CWC完成签到,获得积分10
26秒前
27秒前
QI发布了新的文献求助10
30秒前
30秒前
深情安青应助科研通管家采纳,获得10
31秒前
小小富应助科研通管家采纳,获得10
32秒前
Orange应助科研通管家采纳,获得10
32秒前
Akim应助科研通管家采纳,获得10
32秒前
香蕉觅云应助科研通管家采纳,获得10
32秒前
32秒前
32秒前
思源应助科研通管家采纳,获得10
32秒前
32秒前
32秒前
32秒前
华仔应助科研通管家采纳,获得10
32秒前
32秒前
英吉利25发布了新的文献求助20
34秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A new approach to the extrapolation of accelerated life test data 500
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3954521
求助须知:如何正确求助?哪些是违规求助? 3500524
关于积分的说明 11099808
捐赠科研通 3230997
什么是DOI,文献DOI怎么找? 1786258
邀请新用户注册赠送积分活动 869904
科研通“疑难数据库(出版商)”最低求助积分说明 801717